Company Focus
Chugai
Latest Chugai News
Pharmaceutical
Japanese drugmaker Chugai Pharmaceutical has announced its financial results for the third quarter of fiscal year 2024. 28 October 2024
Related News
Insights
Company Spotlight
A biotechnology company targeting transcription factors to discover precision medicines for cancer and other diseases.
Latest News & Features of interest to Chugai
Pharmaceutical
The market for anaplastic lymphoma kinase (ALK) inhibitors is projected to expand in the coming years, fueled by an increasing number of cancer diagnoses and heightened awareness of these therapies. 2 September 2024
Biotechnology
Chinese biopharma Hutchmed on Friday announced that it has voluntarily withdrawn its supplemental New Drug Application (NDA) in China for fruquintinib. 2 September 2024
Pharmaceutical
Jacobio Pharma announced that it has granted the China rights to KRAS G12C inhibitor glecirasib and SHP2 inhibitor JAB-3312 to Shanghai Allist Pharmaceuticals. 2 September 2024
Biotechnology
Pierre Fabre Laboratories has announced that the European Commission (EC) has approved Braftovi (encorafenib) in combination with Mektovi (binimetinib) for the treatment of adults with advanced non-small cell lung cancer (NSCLC) with a BRAFV600E mutation. 30 August 2024
Biotechnology
While it may already be one of the world’s top-selling drugs across any therapy area, Merck & Co’s Keytruda (pembrolizumab) has not been successful in every indication and combination that it has been tried in across the anti-PD-1 therapy’s vast development program in oncology. 30 August 2024
Pharmaceutical
NuCana announced that the NuTide:323 study is being discontinued following a pre-planned initial analysis and recommendation from the NuTide:323 Study steering committee. 30 August 2024
Biotechnology
Marseille-based ImCheck Therapeutics has received 20.2 million euros ($22.4 million) in non-dilutive funding as part of the i-Démo call for projects under the France 2030 Plan operated by Bpifrance on behalf of the French government. 29 August 2024
Pharmaceutical
Japanese drugmaker Chugai Pharmaceutical says it will transfer the business of the secondary hyperparathyroidism drug Oxarol for Injection (maxacalcitol) to LTL Pharma in Japan. 29 August 2024
Biosimilars
Drug development consultancy Certara has published a report on the Inflation Reduction Act’s (IRA) impact on oncology biosimilar uptake. 29 August 2024
Biotechnology
German pharma major Bayer today announced it has entered into a collaboration and license agreement with US biotech start-up NextRNA Therapeutics to develop small molecule therapeutics targeting lncRNAs in oncology. 28 August 2024
Latest In Brief for Chugai
Pharmaceutical
University Medical Center Groningen (UMCG) and SHINE Europe have secured a 10.5 million euro ($11 million) grant to advance European production of terbium isotopes for cancer treatments. 17 October 2024
Latest Relevant Ones To Watch News
Although it is seeing a downturn in sales and profits, German biotech BioNTech is continuing to acquire assets with the cash pile it made through the covid pandemic, notably iis Comirnaty vaccine that was developed with Pfizer (NYSE: PFE). 13 November 2024
30 October 2024
28 October 2024
26 October 2024
23 October 2024
Relevant Ones to Watch Companies
Refine Search
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze